<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NIPENT- pentostatin injection, powder, lyophilized, for solution </strong><br>Hospira, Inc.<br></p></div>
<h1><span class="Bold">NIPENT<span class="Sup">TM</span> (pentostatin for injection) </span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="f841c326-b744-45d0-aa59-6c2d75d2be87"></a><a name="section-1"></a><p></p>
<p class="First">Rx only                                                                                                                                          <a name="id-13929783"></a><img alt="Novation Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=151c6d2e-1af1-4c13-96ec-de3228c6efb3&amp;name=novation-logo-02.jpg"></p>
</div>
<div class="Warning">
<a name="df7c877b-796a-4966-a70b-ea71bec30553"></a><a name="section-2"></a><p></p>
<h1>WARNING</h1>
<p class="First">NIPENT should be administered under the supervision of a physician qualified and experienced in the use of cancer chemotherapeutic agents. The use of higher doses than those specified (see <span class="Bold"><a href="#fb27b541-cbba-4769-89fe-aeedc793d4fa">DOSAGE AND ADMINISTRATION</a></span>) is not recommended. Dose-limiting severe renal, liver, pulmonary, and CNS toxicities occurred in Phase 1 studies that used NIPENT at higher doses (20-50 mg/m<span class="Sup">2</span> in divided doses over 5 days) than recommended.</p>
<p>In a clinical investigation in patients with refractory <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span> using NIPENT at the recommended dose in combination with fludarabine phosphate, 4 of 6 patients entered in the study had severe or fatal pulmonary toxicity. The use of NIPENT in combination with fludarabine phosphate is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="eee5fbef-43c5-4a20-a96e-74aecba3364e"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">NIPENT<span class="Sup">TM</span> (pentostatin for injection) is supplied as a sterile, apyrogenic, lyophilized powder in single-dose vials for intravenous administration. Each vial contains 10 mg of pentostatin and 50 mg of Mannitol, USP. The pH of the final product is maintained between 7.0 and 8.5 by addition of sodium hydroxide or hydrochloric acid.</p>
<p>Pentostatin, also known as 2’-deoxycoformycin (DCF), is a potent inhibitor of the enzyme adenosine deaminase and is isolated from fermentation cultures of <span class="Emphasis"><span class="Italics">Streptomyces antibioticus</span></span>. Pentostatin is known chemically as (R)-3-(2-deoxy-ß-D-erythropentofuranosyl)3,6,7,8 tetrahydroimidazo[4,5d][1,3]diazepin-8-ol with a molecular formula of C<span class="Sub">11</span>H<span class="Sub">16</span>N<span class="Sub">4</span>O<span class="Sub">4</span> and a molecular weight of 268.27. The molecular structure of pentostatin is:</p>
<div class="Figure">
<a name="id282"></a><img alt="structural formula pentostatin" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=151c6d2e-1af1-4c13-96ec-de3228c6efb3&amp;name=nipent1-figure-1-x431508-1.jpg">
</div>
<p>Pentostatin is a white to off-white solid, freely soluble in distilled water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="f2539b92-df84-4900-bdbe-d24df7df6cdd"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="Emphasis"><span class="Bold">Mechanism of Action</span></span> </p>
<p>Pentostatin is a potent transition state inhibitor of the enzyme adenosine deaminase (ADA). The greatest activity of ADA is found in cells of the lymphoid system with T-cells having higher activity than B-cells, and T-cell malignancies having higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA, particularly in the presence of adenosine or deoxyadenosine, leads to cytotoxicity, and this is believed to be due to elevated intracellular levels of dATP which can block DNA synthesis through inhibition of ribonucleotide reductase. Pentostatin can also inhibit RNA synthesis as well as cause increased DNA damage. In addition to elevated dATP, these mechanisms may also contribute to the overall cytotoxic effect of pentostatin. The precise mechanism of pentostatin’s antitumor effect, however, in <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> is not known.</p>
<p><span class="Emphasis"><span class="Bold">Pharmacokinetics/Drug Metabolism</span></span> </p>
<p>A tissue distribution and whole-body autoradiography study in the rat revealed that radioactivity concentrations were highest in the kidneys with very little central nervous system penetration.</p>
<p>In man, following a single dose of 4 mg/m<span class="Sup">2</span> of pentostatin infused over 5 minutes, the distribution half-life was 11 minutes, the mean terminal half-life was 5.7 hours, the mean plasma clearance was 68 mL/min/m<span class="Sup">2</span>, and approximately 90% of the dose was excreted in the urine as unchanged pentostatin and/or metabolites as measured by adenosine deaminase inhibitory activity. The plasma protein binding of pentostatin is low, approximately 4%.</p>
<p>A positive correlation was observed between pentostatin clearance and creatinine clearance (CrCl) in patients with creatinine clearance values ranging from 60 mL/min to 130 mL/min.<span class="Sup">1</span> Pentostatin half-life in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl &lt;50 mL/min, n=2) was 18 hours, which was much longer than that observed in patients with normal renal function (CrCl &gt;60 mL/min, n=14), about 6 hours.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="bb51f86c-c876-482e-b380-f79a06996313"></a><a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">The following table provides efficacy results for 4 groups (columns) of patients with <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span>: patients who initially received NIPENT, patients who initially received alpha-interferon (IFN), and 2 different groups of patients who received NIPENT after proving to be refractory to, or intolerant of IFN therapy. The first 2 groups represent treatment results from the SWOG 8691 study, a large multicenter study comparing NIPENT and IFN in untreated (frontline) patients with confirmed <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span>. The third group represents evaluable patients from the SWOG study who crossed over to NIPENT after initially receiving IFN. The fourth group, labeled NCI Phase 2 studies, displays pooled results of 2 noncomparative studies (MD Anderson and CALGB), in which NIPENT was used to treat patients with confirmed IFN-refractory disease.</p>
<p>In the SWOG 8691 study, NIPENT was administered at a dose of 4 mg/m<span class="Sup">2</span> every 2 weeks. After 6 months of treatment, patients were evaluated for response. If a complete response was achieved, 2 additional doses of NIPENT were administered and then discontinued. If a partial response was achieved, NIPENT was continued for up to an additional 6 months. NIPENT was discontinued for stable disease after 6 months or progressive disease after 2 months of therapy. IFN was administered 3 million units subcutaneously 3 times per week. Patients who achieved a complete or partial response after 6 months of treatment continued on IFN for another 6 months. IFN was discontinued if patients did not achieve a complete or partial response after 6 months of initial treatment or progressed after 2 months. This study allowed crossover of patients intolerant of, or refractory to, initial treatment. </p>
<p>Interferon-refractory patients enrolled into the MD Anderson study received NIPENT at a dose of 4 mg/m<span class="Sup">2</span> every other week for 3 months and responding patients received 3 additional months. CALGB patients received 4 mg/m<span class="Sup">2</span> of NIPENT every other week for 3 months and responding patients were treated monthly for up to 9 additional months. Almost all patients had a PS of 0 to 2 in the Phase 2 and 3 studies. </p>
<p>For each study, a complete response (CR) required clearing of the peripheral blood and bone marrow of all hairy cells, normalization of organomegaly and <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> by physical examination, and recovery of hemoglobin to at least 12 g/dL, platelet count to at least 100,000/mm<span class="Sup">3</span>, and granulocyte count to at least 1500/mm<span class="Sup">3</span>. A partial response (PR) required that the percentage of hairy cells in the blood and bone marrow decrease by more than 50%, enlarged organs and lymph nodes decrease by more than 50% by physical examination, and hematologic parameters had to meet the same criteria as for complete response. The table below reports the response rate for 2 groups of patients: (1) Evaluable, ie, patients who could be evaluated for response and (2) Intent-to-Treat, ie, patients diagnosed with <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span>.</p>
<table width="100%">
<col width="33%">
<col width="15%">
<col width="15%">
<col width="3%">
<col width="18%">
<col width="15%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="6" valign="top">NR = Not reached by Kaplan-Meier method; ANC = Absolute neutrophil count.<br><span class="Sup">a</span> Evaluable patients<br><span class="Sup">b</span> Patients either refractory to, or intolerant of, IFN<br><span class="Sup">c</span> Kaplan-Meier estimate</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"></td>
<td class="Botrule Toprule" align="center" colspan="2" valign="top"><p class="First">FRONTLINE</p></td>
<td class="Toprule" align="center" valign="top"><p class="First"> </p></td>
<td class="Botrule Toprule" align="center" colspan="2" valign="top"><p class="First">IFN-REFRACTORY<span class="Sup">a</span></p></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="top">
<p class="First"><br>Parameter</p>
<p> </p>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First">Evaluable</p>
<p>NIPENT</p>
<p>N = 138</p>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First">Evaluable</p>
<p>IFN</p>
<p>N=130</p>
</td>
<td class="Botrule" align="center" valign="top"><p class="First"> </p></td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First">SWOG 8691<span class="Sup">b</span></p>
<p>Crossover</p>
<p>N=79</p>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First">NCI Phase 2</p>
<p>Studies</p>
<p>N=44</p>
</td>
</tr>
<tr><td class="Toprule" colspan="6" valign="top"><p class="First">Response Rates (%)</p></td></tr>
<tr>
<td valign="top"><p class="First">     Evaluable CR</p></td>
<td align="center" valign="top"><p class="First">84</p></td>
<td align="center" valign="top"><p class="First">18</p></td>
<td align="center" valign="top"><p class="First"> </p></td>
<td align="center" valign="top"><p class="First">85</p></td>
<td align="center" valign="top"><p class="First">58</p></td>
</tr>
<tr>
<td valign="top"><p class="First">                      PR</p></td>
<td align="center" valign="top"><p class="First">6</p></td>
<td align="center" valign="top"><p class="First">24</p></td>
<td align="center" valign="top"><p class="First"> </p></td>
<td align="center" valign="top"><p class="First">4</p></td>
<td align="center" valign="top"><p class="First">28</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Emphasis"><span class="Italics">     Intent-to-Treat</span></span></p></td>
<td align="center" valign="top"><p class="First"><span class="Emphasis"><span class="Italics">N=170</span></span></p></td>
<td align="center" valign="top"><p class="First"><span class="Emphasis"><span class="Italics">N=170</span></span></p></td>
<td align="center" valign="top"><p class="First"> </p></td>
<td align="center" valign="top"><p class="First"> </p></td>
<td align="center" valign="top"><p class="First"> </p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Emphasis"><span class="Italics">                      CR</span></span></p></td>
<td align="center" valign="top"><p class="First"><span class="Emphasis"><span class="Italics">68</span></span></p></td>
<td align="center" valign="top"><p class="First"><span class="Emphasis"><span class="Italics">14</span></span></p></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First"> </p></td>
<td align="center" valign="top"><p class="First"> </p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Emphasis"><span class="Italics">                      PR</span></span></p></td>
<td align="center" valign="top"><p class="First"><span class="Emphasis"><span class="Italics">5</span></span></p></td>
<td align="center" valign="top"><p class="First"><span class="Emphasis"><span class="Italics">18</span></span></p></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First"> </p></td>
<td align="center" valign="top"><p class="First"> </p></td>
</tr>
<tr><td colspan="6" valign="top"><p class="First">Median Time to Response (months)</p></td></tr>
<tr>
<td valign="top"><p class="First">                      CR</p></td>
<td align="center" valign="top"><p class="First">6.6</p></td>
<td align="center" valign="top"><p class="First">11.5</p></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First">6.0</p></td>
<td align="center" valign="top"><p class="First">4.2</p></td>
</tr>
<tr>
<td valign="top"><p class="First">                       PR</p></td>
<td align="center" valign="top"><p class="First">4.0</p></td>
<td align="center" valign="top"><p class="First">6.2</p></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First">5.8</p></td>
<td align="center" valign="top"><p class="First">—</p></td>
</tr>
<tr><td colspan="6" valign="top"><p class="First">Median Duration of Response (months)</p></td></tr>
<tr>
<td valign="top"><p class="First">                      CR</p></td>
<td align="center" valign="top"><p class="First">NR</p></td>
<td align="center" valign="top"><p class="First">8.3</p></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First">NR</p></td>
<td align="center" valign="top">
<p class="First">&gt;7.7<span class="Sup">c</span> (CALGB)</p>
<p>&gt;15.2<span class="Sup">c</span> (MDA)</p>
</td>
</tr>
<tr>
<td valign="top"><p class="First">                      PR</p></td>
<td align="center" valign="top"><p class="First">NR</p></td>
<td align="center" valign="top"><p class="First">15.2</p></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First">NR</p></td>
<td align="center" valign="top"><p class="First">—</p></td>
</tr>
<tr><td colspan="6" valign="top"><p class="First">% Estimated to be in Response After 24 Months</p></td></tr>
<tr>
<td valign="top"><p class="First">                      CR</p></td>
<td align="center" valign="top"><p class="First">76</p></td>
<td align="center" valign="top"><p class="First">16</p></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First">85</p></td>
<td align="center" valign="top"><p class="First">—</p></td>
</tr>
<tr>
<td valign="top"><p class="First">                      PR</p></td>
<td align="center" valign="top"><p class="First">50</p></td>
<td align="center" valign="top"><p class="First">21</p></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First">—</p></td>
<td align="center" valign="top"><p class="First">—</p></td>
</tr>
<tr><td colspan="6" valign="top"><p class="First">Median Time to Recovery (days)</p></td></tr>
<tr>
<td valign="top"><p class="First">     ANC (1500/mm<span class="Sup">3</span>)</p></td>
<td align="center" valign="top"><p class="First">70</p></td>
<td align="center" valign="top"><p class="First">106</p></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First">—</p></td>
<td align="center" valign="top"><p class="First">—</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">     Platelets (100,000/mm<span class="Sup">3</span>)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">22</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">36</p></td>
<td class="Botrule" valign="top"></td>
<td class="Botrule" align="center" valign="top"><p class="First">—</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">—</p></td>
</tr>
</tbody>
</table>
<p>The results show that frontline patients treated with NIPENT achieved a significantly higher rate of response than those treated with IFN. The time to recovery of neutrophil and platelet counts was shorter with NIPENT treatment and the estimated duration of response was longer. The response rate in IFN-refractory patients treated with NIPENT was similar to that in NIPENT-treated frontline patients. At a median follow-up duration of 46 months, there was no statistically significant difference in survival between <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> patients initially treated with NIPENT and those initially treated with IFN. However, no definite conclusions regarding survival can be made from these results because they are complicated by the fact that the majority of IFN patients crossed over to NIPENT treatment.</p>
<p>In the Phase 3 SWOG study, 25 patients with <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> died during treatment or follow-up: 18 patients had last received NIPENT (3 of whom had crossed over from IFN), and 7 patients had last received IFN (1 of whom crossed over from NIPENT). Eleven of the 25 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> occurred within 60 days of the last dose of treatment. Of these, <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> was cited by the investigators as a contributory cause for 1 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in the NIPENT group and 3 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the IFN group. Additionally, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> contributed to the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> of 3 patients in the NIPENT group and 2 patients in the IFN group. Approximately 4% of <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> patients, in each arm, died more than 60 days after the last dose of either treatment and there was no outstanding cause of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> among these patients.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="bcd92aa5-c045-4836-b294-3188de2a23c4"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> patients with active disease as defined by clinically significant <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, or disease-related symptoms.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="be9031c4-aa21-4c52-b215-ce6ef12e70f1"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">NIPENT is contraindicated in patients who have demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to NIPENT.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="c8269f50-aab5-48d6-8195-46a29ff40699"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See <span class="Bold"><a href="#df7c877b-796a-4966-a70b-ea71bec30553">Boxed Warning</a></span><span class="Emphasis">.</span></p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> may experience <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> primarily during the first few courses of treatment. Patients with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> prior to NIPENT treatment have in some cases developed worsening of their condition leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, whereas others have achieved complete response. Patients with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be treated only when the potential benefit of treatment justifies the potential risk to the patient. Efforts should be made to control the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> before treatment is initiated or resumed.</p>
<p>In patients with progressive <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span>, the initial courses of NIPENT treatment were associated with worsening of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Therefore, frequent monitoring of complete blood counts during this time is necessary. If severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> continues beyond the initial cycles, patients should be evaluated for disease status, including a <span class="product-label-link" type="condition" conceptid="4043761" conceptname="Bone marrow examination">bone marrow examination</span>.</p>
<p>Elevations in liver function tests occurred during treatment with NIPENT and were generally reversible. </p>
<p>Renal toxicity was observed at higher doses in early studies; however, in patients treated at the recommended dose, elevations in serum creatinine were usually minor and reversible. There were some patients who began treatment with normal renal function who had evidence of mild to moderate toxicity at a final assessment. (See <span class="Bold"><a href="#fb27b541-cbba-4769-89fe-aeedc793d4fa">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span>, occasionally severe, were commonly reported and may worsen with continued treatment. Withholding of treatment may be required. (See <span class="Bold"><a href="#fb27b541-cbba-4769-89fe-aeedc793d4fa">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p><span class="product-label-link" type="condition" conceptid="261600" conceptname="Acute pulmonary edema">Acute pulmonary edema</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported in the literature in patients treated with pentostatin in combination with carmustine, etoposide and high dose cyclophosphamide as part of the ablative regimen for bone marrow transplant.</p>
<p><span class="Emphasis"><span class="Bold">Pregnancy Category D</span></span></p>
<p>Pentostatin can cause fetal harm when administered to a pregnant woman. Pentostatin was administered intravenously at doses of 0, 0.01, 0.1, or 0.75 mg/kg/day (0, 0.06, 0.6, and 4.5 mg/m<span class="Sup">2</span>) to pregnant rats on days 6 through 15 of gestation. Drug-related maternal toxicity occurred at doses of 0.1 and 0.75 mg/kg/day (0.6 and 4.5 mg/m<span class="Sup">2</span>). Teratogenic effects were observed at 0.75 mg/kg/day (4.5 mg/m<span class="Sup">2</span>) manifested by increased incidence of various skeletal malformations. In a dose range-finding study, pentostatin was administered intravenously to rats at doses of 0, 0.05, 0.1, 0.5, 0.75, or 1 mg/kg/day (0, 0.3, 0.6, 3, 4.5, 6 mg/m<span class="Sup">2</span>), on days 6 through 15 of gestation. <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">Fetal malformations</span> that were observed were an <span class="product-label-link" type="condition" conceptid="4077297" conceptname="Congenital omphalocele">omphalocele</span> at 0.05 mg/kg (0.3 mg/m<span class="Sup">2</span>), <span class="product-label-link" type="condition" conceptid="4218764" conceptname="Gastroschisis">gastroschisis</span> at 0.75 mg/kg and 1 mg/kg (4.5 and 6 mg/m<span class="Sup">2</span>), and a flexure defect of the hindlimbs at 0.75 mg/kg (4.5 mg/m<span class="Sup">2</span>). Pentostatin was also shown to be teratogenic in mice when administered as a single 2 mg/kg (6 mg/m<span class="Sup">2</span>) intraperitoneal injection on day 7 of gestation. Pentostatin was not teratogenic in rabbits when administered intravenously on days 6 through 18 of gestation at doses of 0, 0.005, 0.01, or 0.02 mg/kg/day (0, 0.015, 0.03, or 0.06 mg/m<span class="Sup">2</span>); however maternal toxicity, abortions, early deliveries, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> occurred in all drug-treated groups. There are no adequate and well-controlled studies in pregnant women. If NIPENT is used during pregnancy, or if the patient becomes pregnant while taking (receiving) this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential receiving NIPENT should be advised to avoid becoming pregnant.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="dcac672f-3e95-4951-859c-1598551bd494"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="f44f7a88-87ba-4b6d-a999-efe42eb2f0ae"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">Therapy with NIPENT requires regular patient observation and monitoring of hematologic parameters and blood chemistry values. If severe adverse reactions occur, the drug should be withheld (see <span class="Bold"><a href="#fb27b541-cbba-4769-89fe-aeedc793d4fa">DOSAGE AND ADMINISTRATION</a></span>), and appropriate corrective measures should be taken according to the clinical judgment of the physician.</p>
<p>NIPENT treatment should be withheld or discontinued in patients showing evidence of nervous system toxicity.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="bcf24801-1cfe-4f66-adec-21b8ab406bad"></a><a name="section-8.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be advised of the signs and symptoms of adverse events associated with NIPENT therapy. (See <span class="Bold"><a href="#d9eb4398-630b-4691-ba7d-7e806a4f6cf9">ADVERSE REACTIONS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="fd912a5b-1fbb-4f2c-b3c5-93bcaf62f8f6"></a><a name="section-8.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Prior to initiating therapy with NIPENT, renal function should be assessed with a serum creatinine and/or a creatinine clearance assay. (See <span class="Bold"><a href="#f2539b92-df84-4900-bdbe-d24df7df6cdd">CLINICAL PHARMACOLOGY </a></span>and <span class="Bold"><a href="#fb27b541-cbba-4769-89fe-aeedc793d4fa">DOSAGE AND ADMINISTRATION</a></span>.) Complete blood counts and serum creatinine should be performed before each dose of NIPENT and at other appropriate periods during therapy (see <span class="Bold"><a href="#fb27b541-cbba-4769-89fe-aeedc793d4fa">DOSAGE AND ADMINISTRATION</a></span>). Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> has been observed following the early courses of treatment with NIPENT and therefore frequent monitoring of complete blood counts is recommended during this time. If hematologic parameters do not improve with subsequent courses, patients should be evaluated for disease status, including a <span class="product-label-link" type="condition" conceptid="4043761" conceptname="Bone marrow examination">bone marrow examination</span>. Periodic monitoring of the peripheral blood for hairy cells should be performed to assess the response to treatment.</p>
<p>In addition, bone marrow aspirates and biopsies may be required at 2 to 3 month intervals to assess the response to treatment.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="bf5302e8-719c-4a57-a5fe-93e0b6c47e6f"></a><a name="section-8.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Allopurinol and NIPENT are both associated with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>. Based on clinical studies in 25 refractory patients who received both NIPENT and allopurinol, the combined use of NIPENT and allopurinol did not appear to produce a higher incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> than observed with NIPENT alone. There has been a report of one patient who received both drugs and experienced a <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">hypersensitivity vasculitis</span> that resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. It was unclear whether this adverse event and subsequent <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> resulted from the drug combination.</p>
<p>Biochemical studies have demonstrated that pentostatin enhances the effects of vidarabine, a purine nucleoside with antiviral activity. The combined use of vidarabine and NIPENT may result in an increase in adverse reactions associated with each drug. The therapeutic benefit of the drug combination has not been established. </p>
<p>The combined use of NIPENT and fludarabine phosphate is not recommended because it may be associated with an increased risk of fatal pulmonary toxicity (see <span class="Bold"><a href="#c8269f50-aab5-48d6-8195-46a29ff40699">WARNINGS</a></span>).</p>
<p><span class="product-label-link" type="condition" conceptid="261600" conceptname="Acute pulmonary edema">Acute pulmonary edema</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported in the literature in patients treated with pentostatin in combination with carmustine, etoposide and high dose cyclophosphamide as part of the ablative regimen for bone marrow transplant.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="ebaca014-64db-426f-9860-1753ec164962"></a><a name="section-8.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Emphasis"><span class="Bold">Carcinogenesis: </span></span>No animal carcinogenicity studies have been conducted with pentostatin.</p>
<p><span class="Emphasis"><span class="Bold">Mutagenesis: </span></span>Pentostatin was nonmutagenic when tested in <span class="Emphasis"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span></span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA-98, TA-1535, TA-1537, and TA-1538. When tested with <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA-100, a repeatable statistically significant response trend was observed with and without metabolic activation. The response was 2.1 to 2.2 fold higher than the background at 10 mg/plate, the maximum possible drug concentration. Formulated pentostatin was clastogenic in the <span class="Emphasis"><span class="Italics">in vivo</span></span> mouse bone marrow micronucleus assay at 20, 120, and 240 mg/kg. Pentostatin was not mutagenic to V79 Chinese hamster lung cells at the HGPRT locus exposed 3 hours to concentrations of 1 to 3 mg/mL, with or without metabolic activation. Pentostatin did not significantly increase chromosomal aberrations in V79 Chinese hamster lung cells exposed 3 hours to 1 to 3 mg/mL in the presence or absence of metabolic activation.</p>
<p><span class="Emphasis"><span class="Bold">Impairment of Fertility: </span></span>No fertility studies have been conducted in animals; however, in a 5-day intravenous toxicity study in dogs, mild seminiferous tubular degeneration was observed with doses of 1 and 4 mg/kg. The possible adverse effects on fertility in humans have not been determined.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="e235744d-4002-4a1d-9c26-b82e7c9a78e5"></a><a name="section-8.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Emphasis"><span class="Bold">Pregnancy Category D: </span></span>(See <span class="Bold"><a href="#c8269f50-aab5-48d6-8195-46a29ff40699">WARNINGS</a></span>)</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="f0b0422c-b88f-469b-9aa6-a5c003998e75"></a><a name="section-8.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether NIPENT is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from pentostatin, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of NIPENT to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="f02aa157-2dbf-47cf-923d-138c00c9c55a"></a><a name="section-8.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in children or adolescents have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="d9eb4398-630b-4691-ba7d-7e806a4f6cf9"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Most patients treated for <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> in the five NCI-sponsored Phase 2 studies and the Phase 3 SWOG study experienced an adverse event. The following table lists the most frequently occurring adverse events in patients treated with NIPENT (both frontline and IFN-refractory patients) compared with IFN (frontline only), regardless of drug association. The drug association of some adverse events is uncertain as they may be associated with the disease itself (eg, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, hematologic suppression), but other events, such as the <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, and <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, can in many cases be attributed to the drug. Most adverse events that were assessed for severity were either mild or moderate, and diminished in frequency with continued therapy.</p>
<table width="100%">
<col width="52%">
<col width="16%">
<col width="14%">
<col width="18%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">NR = Not Reported<br><span class="Sup">a</span> Occurring in more than 10% of patients, in any group, regardless of drug association<br><span class="Sup">b</span> Includes only <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br><span class="Sup">c</span> These figures represent only unspecified <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Refer to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> table.<br><span class="Sup">d</span> Elevated liver enzymes and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorder</span> for SWOG</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" valign="top"></td>
<td class="Botrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">Percent of Patients</p></td>
</tr>
<tr>
<td class="Botrule Toprule" valign="top"><p class="First">All Adverse Events<span class="Sup">a</span></p></td>
<td class="Botrule Toprule" align="center" valign="bottom">
<p class="First">Frontline,</p>
<p>Treated</p>
<p>With NIPENT</p>
<p>N=180</p>
</td>
<td class="Botrule Toprule" align="center" valign="bottom">
<p class="First">Frontline,</p>
<p>Treated</p>
<p>With IFN</p>
<p>N=176</p>
</td>
<td class="Botrule Toprule" align="center" valign="bottom">
<p class="First">IFN-Refractory,</p>
<p>Treated With</p>
<p>NIPENT</p>
<p>N=197</p>
</td>
</tr>
<tr>
<td class="Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td class="Toprule" align="center" valign="top"><p class="First">63</p></td>
<td class="Toprule" align="center" valign="top"><p class="First">22</p></td>
<td class="Toprule" align="center" valign="top"><p class="First"> 53<span class="Sup">b</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </p></td>
<td align="center" valign="top"><p class="First">46</p></td>
<td align="center" valign="top"><p class="First">59</p></td>
<td align="center" valign="top"><p class="First">42</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </p></td>
<td align="center" valign="top"><p class="First">43</p></td>
<td align="center" valign="top"><p class="First">30</p></td>
<td align="center" valign="top"><p class="First">26</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </p></td>
<td align="center" valign="top"><p class="First">42</p></td>
<td align="center" valign="top"><p class="First">55</p></td>
<td align="center" valign="top"><p class="First">29</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> </p></td>
<td align="center" valign="top"><p class="First">22</p></td>
<td align="center" valign="top"><p class="First">15</p></td>
<td align="center" valign="top"><p class="First">60</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> </p></td>
<td align="center" valign="top"><p class="First">21</p></td>
<td align="center" valign="top"><p class="First">6</p></td>
<td align="center" valign="top"><p class="First">10</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span>/Increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> </p></td>
<td align="center" valign="top"><p class="First">20</p></td>
<td align="center" valign="top"><p class="First">15</p></td>
<td align="center" valign="top"><p class="First">17</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> </p></td>
<td align="center" valign="top"><p class="First">19</p></td>
<td align="center" valign="top"><p class="First">36</p></td>
<td align="center" valign="top"><p class="First">11</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span> </p></td>
<td align="center" valign="top"><p class="First">19</p></td>
<td align="center" valign="top"><p class="First">34</p></td>
<td align="center" valign="top"><p class="First">11</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td align="center" valign="top"><p class="First">17</p></td>
<td align="center" valign="top"><p class="First">29</p></td>
<td align="center" valign="top"><p class="First">13</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td align="center" valign="top"><p class="First">17</p></td>
<td align="center" valign="top"><p class="First">17</p></td>
<td align="center" valign="top"><p class="First">15</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span> </p></td>
<td align="center" valign="top"><p class="First">16</p></td>
<td align="center" valign="top"><p class="First">15</p></td>
<td align="center" valign="top"><p class="First">4</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> </p></td>
<td align="center" valign="top"><p class="First">13</p></td>
<td align="center" valign="top"><p class="First">10</p></td>
<td align="center" valign="top"><p class="First">16</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Infection</span> </p></td>
<td align="center" valign="top"><p class="First">13</p></td>
<td align="center" valign="top"><p class="First">8</p></td>
<td align="center" valign="top"><p class="First">16</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> </p></td>
<td align="center" valign="top"><p class="First">12</p></td>
<td align="center" valign="top"><p class="First">13</p></td>
<td align="center" valign="top"><p class="First">10</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></p></td>
<td align="center" valign="top"><p class="First">12</p></td>
<td align="center" valign="top"><p class="First">7</p></td>
<td align="center" valign="top"><p class="First">5</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span> </p></td>
<td align="center" valign="top"><p class="First">11</p></td>
<td align="center" valign="top"><p class="First">15</p></td>
<td align="center" valign="top"><p class="First">10</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> </p></td>
<td align="center" valign="top"><p class="First">11</p></td>
<td align="center" valign="top"><p class="First">13</p></td>
<td align="center" valign="top"><p class="First">8</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td align="center" valign="top"><p class="First">8</p></td>
<td align="center" valign="top"><p class="First">5</p></td>
<td align="center" valign="top"><p class="First">35</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </p></td>
<td align="center" valign="top"><p class="First">8</p></td>
<td align="center" valign="top"><p class="First">19</p></td>
<td align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> </p></td>
<td align="center" valign="top"><p class="First">8</p></td>
<td align="center" valign="top"><p class="First">11</p></td>
<td align="center" valign="top"><p class="First">10</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span>/Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span> </p></td>
<td align="center" valign="top"><p class="First">8</p></td>
<td align="center" valign="top"><p class="First">21</p></td>
<td align="center" valign="top"><p class="First">10</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infection</span> </p></td>
<td align="center" valign="top"><p class="First">8</p></td>
<td align="center" valign="top"><p class="First">17</p></td>
<td align="center" valign="top"><p class="First">NR</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </p></td>
<td align="center" valign="top"><p class="First">7<span class="Sup">c</span></p></td>
<td align="center" valign="top"><p class="First">2<span class="Sup">c</span></p></td>
<td align="center" valign="top"><p class="First">36</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </p></td>
<td align="center" valign="top"><p class="First">6</p></td>
<td align="center" valign="top"><p class="First">14</p></td>
<td align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> </p></td>
<td align="center" valign="top"><p class="First">6</p></td>
<td align="center" valign="top"><p class="First">6</p></td>
<td align="center" valign="top"><p class="First">32</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorder</span> </p></td>
<td align="center" valign="top"><p class="First">4</p></td>
<td align="center" valign="top"><p class="First">5</p></td>
<td align="center" valign="top"><p class="First">17</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reaction</span> </p></td>
<td align="center" valign="top"><p class="First">2</p></td>
<td align="center" valign="top"><p class="First">1</p></td>
<td align="center" valign="top"><p class="First">11</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Hepatic Disorder/Elevated Liver Function Tests<span class="Sup">d</span></p></td>
<td align="center" valign="top"><p class="First">2</p></td>
<td align="center" valign="top"><p class="First">2</p></td>
<td align="center" valign="top"><p class="First">19</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Neurologic Disorder, CNS/CNS Toxicity </p></td>
<td align="center" valign="top"><p class="First">1</p></td>
<td align="center" valign="top"><p class="First">NR</p></td>
<td align="center" valign="top"><p class="First">11</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Lung Disorder</span>/Disease </p></td>
<td align="center" valign="top"><p class="First">NR</p></td>
<td align="center" valign="top"><p class="First">1</p></td>
<td align="center" valign="top"><p class="First">12</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td align="center" valign="top"><p class="First">NR</p></td>
<td align="center" valign="top"><p class="First">NR</p></td>
<td align="center" valign="top"><p class="First">22</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">Genitourinary Disorder </p></td>
<td class="Botrule" align="center" valign="top"><p class="First">NR</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">NR</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">15</p></td>
</tr>
</tbody>
</table>
<p>The total incidence for all types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is considerably higher for both treatment groups in the SWOG 8691 study than is listed in the table above. An intent-to-treat analysis of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> found that 38% of patients treated with NIPENT and 34% of patients treated with IFN averaged 2.4 and 1.9 documented <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> during treatment, respectively. The following table lists the different types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that were reported as adverse events during the initial phase of the SWOG study. There were no apparent differences in the types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> between the 2 treatment groups, with the possible exception of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> which was reported more frequently for NIPENT (8%) than for IFN (1%).</p>
<table width="100%">
<col width="43%">
<col width="29%">
<col width="29%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" valign="top"></td>
<td class="Botrule Toprule" align="center" colspan="2" valign="top"><p class="First">Percent of Patients</p></td>
</tr>
<tr>
<td class="Botrule Toprule" valign="top"><p class="First">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First">Frontline, Treated</p>
<p>With NIPENT</p>
<p>N=180</p>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First">Frontline, Treated</p>
<p>With IFN</p>
<p>N=176</p>
</td>
</tr>
<tr>
<td class="Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Infection</span> </p></td>
<td class="Toprule" align="center" valign="top"><p class="First">13</p></td>
<td class="Toprule" align="center" valign="top"><p class="First">  8</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span> </p></td>
<td align="center" valign="top"><p class="First">11</p></td>
<td align="center" valign="top"><p class="First">15</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span> </p></td>
<td align="center" valign="top"><p class="First">  8</p></td>
<td align="center" valign="top"><p class="First">  1</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> </p></td>
<td align="center" valign="top"><p class="First">  8</p></td>
<td align="center" valign="top"><p class="First">11</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infection</span> </p></td>
<td align="center" valign="top"><p class="First">  8</p></td>
<td align="center" valign="top"><p class="First">17</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> (Unspecified) </p></td>
<td align="center" valign="top"><p class="First">  7</p></td>
<td align="center" valign="top"><p class="First">  2</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> </p></td>
<td align="center" valign="top"><p class="First">  6</p></td>
<td align="center" valign="top"><p class="First">  4</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span> </p></td>
<td align="center" valign="top"><p class="First">  6</p></td>
<td align="center" valign="top"><p class="First">  3</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infection</span> </p></td>
<td align="center" valign="top"><p class="First">  5</p></td>
<td align="center" valign="top"><p class="First">  4</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> </p></td>
<td align="center" valign="top"><p class="First">  5</p></td>
<td align="center" valign="top"><p class="First">  7</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span> </p></td>
<td align="center" valign="top"><p class="First">  4</p></td>
<td align="center" valign="top"><p class="First">  2</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">Furunculosis</span> </p></td>
<td align="center" valign="top"><p class="First">  4</p></td>
<td align="center" valign="top"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Herpes Simplex </p></td>
<td align="center" valign="top"><p class="First">  4</p></td>
<td align="center" valign="top"><p class="First">  1</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span> </p></td>
<td align="center" valign="top"><p class="First">  3</p></td>
<td align="center" valign="top"><p class="First">  2</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> </p></td>
<td align="center" valign="top"><p class="First">  3</p></td>
<td align="center" valign="top"><p class="First">  2</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> </p></td>
<td align="center" valign="top"><p class="First">  3</p></td>
<td align="center" valign="top"><p class="First">  3</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span>, Skin </p></td>
<td align="center" valign="top"><p class="First">  2</p></td>
<td align="center" valign="top"><p class="First">  4</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Moniliasis</span>, Oral </p></td>
<td align="center" valign="top"><p class="First">  2</p></td>
<td align="center" valign="top"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>, Skin </p></td>
<td align="center" valign="top"><p class="First">&lt;1</p></td>
<td align="center" valign="top"><p class="First">  3</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">Osteomyelitis</span> </p></td>
<td class="Botrule" align="center" valign="top"><p class="First">  1</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">  0</p></td>
</tr>
</tbody>
</table>
<p>The drug relatedness of the adverse events listed below cannot be excluded. The following adverse events occurred in 3% to 10% of NIPENT-treated patients in the initial phase of the SWOG study:</p>
<p><span class="Emphasis"><span class="Bold">Body as a Whole</span></span>—<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span>, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, Face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></p>
<p><span class="Emphasis"><span class="Bold">Cardiovascular System</span></span>—<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p>
<p><span class="Emphasis"><span class="Bold">Digestive System</span></span>—Dental Abnormalities, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">Gingivitis</span></p>
<p><span class="Emphasis"><span class="Bold">Hemic and Lymphatic System</span></span>—<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></p>
<p><span class="Emphasis"><span class="Bold">Laboratory Deviations</span></span>—Elevated Creatinine</p>
<p><span class="Emphasis"><span class="Bold">Musculoskeletal System</span></span>—<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p>
<p><span class="Emphasis"><span class="Bold">Nervous System</span></span>—<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p>
<p><span class="Emphasis"><span class="Bold">Psychobiologic Function</span></span>—<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></p>
<p><span class="Emphasis"><span class="Bold">Respiratory System</span></span>—<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></p>
<p><span class="Emphasis"><span class="Bold">Skin &amp; Appendages</span></span>—<span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Skin Dry</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></p>
<p>The remaining adverse events which occurred in less than 3% of NIPENT-treated patients during the initial phase of the SWOG study:</p>
<p><span class="Emphasis"><span class="Bold">Body as a Whole</span></span>—Flu-like Symptoms, <span class="product-label-link" type="condition" conceptid="4137607" conceptname="Hangover">Hangover Effect</span>, Neoplasm</p>
<p><span class="Emphasis"><span class="Bold">Cardiovascular System</span></span>—<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina Pectoris</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, A-V Block, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">Extrasystoles Ventricular</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Heart Arrest</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">Pericardial Effusion</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolus</span>, <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">Sinus Arrest</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Thrombophlebitis Deep</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span></p>
<p><span class="Emphasis"><span class="Bold">Digestive System</span></span>—<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">Glossitis</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span></p>
<p><span class="Emphasis"><span class="Bold">Hemic and Lymphatic System</span></span>—<span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">Acute Leukemia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>-Hemolytic, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic Anemia</span></p>
<p><span class="Emphasis"><span class="Bold">Laboratory Deviations</span></span>—<span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></p>
<p><span class="Emphasis"><span class="Bold">Musculoskeletal System</span></span>—<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span></p>
<p><span class="Emphasis"><span class="Bold">Nervous System</span></span>—<span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Dreaming Abnormal</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">Dysarthria</span>, <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">Encephalitis</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">Hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4233749" conceptname="Meningism">Meningism</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">Neuritis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">Paralysis</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">Twitching</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p>
<p><span class="Emphasis"><span class="Bold">Psychobiologic Function</span></span>—Decrease/Loss Libido, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional Lability</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucination</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">Hostility</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">Neurosis</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Thinking Abnormal</span></p>
<p><span class="Emphasis"><span class="Bold">Respiratory System</span></span>—<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">Larynx Edema</span></p>
<p><span class="Emphasis"><span class="Bold">Skin and Appendages</span></span>—<span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechial Rash</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity Reaction</span></p>
<p><span class="Emphasis"><span class="Bold">Special Senses</span></span>—<span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Deafness</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Earache</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Eyes Dry</span>, <span class="product-label-link" type="condition" conceptid="74052" conceptname="Labyrinthitis">Labyrinthitis</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">Lacrimation</span> Disorder, Nonreactive Eye, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">Photophobia</span>, <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">Retinopathy</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>, Unusual Taste, <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">Vision Abnormal</span>, Watery Eyes</p>
<p><span class="Emphasis"><span class="Bold">Urogenital System</span></span>—<span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast Lump</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Kidney Function Abnormal</span>, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Nephropathy</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Renal Stone</span></p>
<p>One patient with <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> treated with NIPENT during another clinical study developed unilateral <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> with <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>.</p>
<p>Nineteen (5%) patients withdrew from the Phase 3 SWOG 8691 study because of adverse events; 9 during initial NIPENT treatment, 4 during NIPENT crossover, 5 during initial IFN treatment, and 1 during both initial IFN treatment and NIPENT crossover. In the Phase 2 studies in IFN-refractory <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span>, 11% of patients withdrew from treatment with NIPENT due to an adverse event.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="b2935828-4b89-4032-a6fd-e66dfb257d71"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No specific antidote for NIPENT <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is known. NIPENT administered at higher doses (20- 50 mg/m<span class="Sup">2</span> in divided doses over 5 days) than recommended was associated with <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to severe renal, hepatic, pulmonary, and CNS toxicity. In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, management would include general supportive measures through any period of toxicity that occurs.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="fb27b541-cbba-4769-89fe-aeedc793d4fa"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">It is recommended that patients receive hydration with 500 to 1,000 mL of 5% Dextrose in 0.5 Normal Saline or equivalent before NIPENT administration. An additional 500 mL of 5% Dextrose or equivalent should be administered after NIPENT is given.</p>
<p>The recommended dosage of NIPENT for the treatment of <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> is 4 mg/m<span class="Sup">2</span> every other week. NIPENT may be administered intravenously by bolus injection or diluted in a larger volume and given over 20 to 30 minutes. (See <span class="Emphasis"><span class="Bold">Preparation of Intravenous Solution</span></span>.)</p>
<p>Higher doses are not recommended.</p>
<p>No <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> injuries were reported in clinical studies.</p>
<p>The optimal duration of treatment has not been determined. In the absence of major toxicity and with observed continuing improvement, the patient should be treated until a complete response has been achieved. Although not established as required, the administration of two additional doses has been recommended following the achievement of a complete response.</p>
<p>All patients receiving NIPENT at 6 months should be assessed for response to treatment. If the patient has not achieved a complete or partial response, treatment with NIPENT should be discontinued.</p>
<p>If the patient has achieved a partial response, NIPENT treatment should be continued in an effort to achieve a complete response. At any time thereafter that a complete response is achieved, two additional doses of NIPENT are recommended. NIPENT treatment should then be stopped. If the best response to treatment at the end of 12 months is a partial response, it is recommended that treatment with NIPENT be stopped.</p>
<p>Withholding or discontinuation of individual doses may be needed when severe adverse reactions occur. Drug treatment should be withheld in patients with severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and withheld or discontinued in patients showing evidence of nervous system toxicity.</p>
<p>NIPENT treatment should be withheld in patients with active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurring during the treatment but may be resumed when the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is controlled.</p>
<p>Patients who have elevated serum creatinine should have their dose withheld and a creatinine clearance determined. There are insufficient data to recommend a starting or a subsequent dose for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance &lt;60 mL/min).</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> should be treated only when the potential benefit justifies the potential risk. Two patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearances 50 to 60 mL/min) achieved complete response without unusual adverse events when treated with 2 mg/m<span class="Sup">2</span>.</p>
<p>No dosage reduction is recommended at the start of therapy with NIPENT in patients with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. In addition, dosage reductions are not recommended during treatment in patients with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> if patients can be otherwise supported hematologically. NIPENT should be temporarily withheld if the absolute neutrophil count <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> during treatment below 200 cells/mm<span class="Sup">3</span> in a patient who had an initial neutrophil count greater than 500 cells/mm<span class="Sup">3</span> and may be resumed when the count returns to predose levels.</p>
<p><span class="Emphasis"><span class="Bold">Preparation of Intravenous Solution</span></span></p>
<dl>
<dt>1.</dt>
<dd>Procedures for proper handling and disposal of anticancer drugs should be followed. Several guidelines on this subject have been published.<span class="Sup">2-7</span> There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate. Spills and wastes should be treated with a 5% sodium hypochlorite solution prior to disposal.</dd>
<dt>2.</dt>
<dd>Protective clothing including polyethylene gloves must be worn.</dd>
<dt>3.</dt>
<dd>Transfer 5 mL of Sterile Water for Injection USP to the vial containing NIPENT and mix thoroughly to obtain complete dissolution of a solution yielding 2 mg/mL. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.</dd>
<dt>4.</dt>
<dd>NIPENT may be given intravenously by bolus injection or diluted in a larger volume (25 to 50 mL) with 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP. Dilution of the entire contents of a reconstituted vial with 25 mL or 50 mL provides a pentostatin concentration of 0.33 mg/mL or 0.18 mg/mL, respectively, for the diluted solutions.</dd>
<dt>5.</dt>
<dd>NIPENT solution when diluted for infusion with 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP does not interact with PVC infusion containers or administration sets at concentrations of 0.18 mg/mL to 0.33 mg/mL.</dd>
</dl>
<p><span class="Emphasis"><span class="Bold">Stability</span></span></p>
<p>NIPENT vials are stable at refrigerated storage temperature 2° to 8° C (36° to 46°F) for the period stated on the package. Vials reconstituted or reconstituted and further diluted as directed may be stored at room temperature and ambient light but should be used within 8 hours because NIPENT contains no preservatives.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="cf3a9781-1cf8-4a19-bdc6-66f155367812"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NIPENT (pentostatin for injection) is supplied as a sterile lyophilized white to off-white powder in single-dose vials containing 10 mg of pentostatin. The vials are packed in individual cartons. <span class="Emphasis"><span class="Bold">NDC 0409-0801-09.</span></span></p>
<p><span class="Emphasis"><span class="Bold">Storage: Store NIPENT vials under refrigerated storage conditions 2° to 8° C (36° to 46°F).</span></span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ee133854-1555-4bd1-b3e6-50c8ec7eca65"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Malspeis L, et al. Clinical pharmacokinetics of 2’-Deoxycoformycin. Cancer Treatment Symposia 2:7-15, 1984.</dd>
<dt>2.</dt>
<dd>Recommendations for the safe handling of parenteral antineoplastic drugs. NIH Publication 83-2621. For sale by the Superintendent of Documents, US Government Printing Office, Washington, DC 20402.</dd>
<dt>3.</dt>
<dd>AMA council Report. Guidelines for handling parenteral antineoplastics. JAMA 253:1590-2, 1985.</dd>
<dt>4.</dt>
<dd>National Study Commission on Cytotoxic Exposure—Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, Sc.D., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115.</dd>
<dt>5.</dt>
<dd>Clinical Oncological Society of Australia: Guidelines and recommendations for safe handling of antineoplastic agents. Med J Australia 1:426-8, 1983.</dd>
<dt>6.</dt>
<dd>Jones RB, et al. Safe handling of chemotherapeutic agents: A report from the Mount Sinai Medical Center. CA: A Cancer Journal for Clinicians 33:258-63, 1983.</dd>
<dt>7.</dt>
<dd>American Society of Hospital Pharmacists technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 47:1033-49, 1990.</dd>
</dl>
<p class="First">                                                                                434063</p>
<p><span class="Emphasis"><span class="Bold">Manufactured by:<br>Hospira, Inc.</span></span><br>Lake Forest, IL 60045 USA</p>
<p>Product of Australia                                                                                                       </p>
<p>N+ and NOVAPLUS are registered trademarks of Novation, LLC.</p>
<p>Revised: 05/2013<br><br><a name="id-554701439"></a><img alt="Novaplus logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=151c6d2e-1af1-4c13-96ec-de3228c6efb3&amp;name=novaplus-logo.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="c4eddb3f-ba69-4438-9fb4-b6b8a10fdc83"></a><a name="section-14"></a><p></p>
<h1>434598</h1>
<div class="Figure">
<a name="id-1508514726"></a><img alt="Carton NDC 0409-0801-09" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=151c6d2e-1af1-4c13-96ec-de3228c6efb3&amp;name=434598.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NIPENT 		
					</strong><br><span class="contentTableReg">pentostatin injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-0801</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PENTOSTATIN</strong> (PENTOSTATIN) </td>
<td class="formItem">PENTOSTATIN</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-0801-09</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020122</td>
<td class="formItem">08/08/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Hospira, Inc.
							(141588017)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>151c6d2e-1af1-4c13-96ec-de3228c6efb3</div>
<div>Set id: 151c6d2e-1af1-4c13-96ec-de3228c6efb3</div>
<div>Version: 1</div>
<div>Effective Time: 20150731</div>
</div>
</div> <div class="DistributorName">Hospira, Inc.</div></p>
</body></html>
